News

Partner to entrepreneurs, innovators and businesses in their quest to realize their full potential

Image

April 5, 2022

Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved drugs for neurological indications, today announced that the efficacy and safety data from its recently completed Phase 3, randomized controlled trial of P2B001 in the management of early Parkinson’s disease...
Learn More

February 8, 2021

Arcellx Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its initial public offering of 9,487,500 shares of its common stock...
Learn More

December 20, 2021

Pi-Cardia ShortCut™ Device Successfully Treats First Patients in Europe

First Dedicated Device to Enable Coronary Access and Prevent Coronary Obstruction During TAVR.
Learn More

December 15, 2021

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components, P2B001 showed comparable efficacy to a marketed extended release (ER) pramipexole with significantly less daytime sleepiness and a superior safety profile. Topline results support P2B001's potential as a first line treatment for people with early Parkinson's disease, with easy administration (once daily with no titration. Company plans to file an NDA in 2022.
Learn More

April 3, 2021

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022.
Learn More

January 14, 2021

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program

Naarden, the Netherlands, January 14, 2021 – NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, today announced completion of a $196M (€160M) Series A funding round.
Learn More

August 18, 2020

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

ImmPACT Bio USA, Inc., a company founded in the FutuRx incubator located in Ness Ziona, Israel, developing novel cell therapies for treating cancer, today announced the closing of a US$ 18 million equity financing round. The financing included OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., RM Global Partners (RMGP) BioPharma Investment Fund, Novartis Venture Fund, Bukwang Pharmaceutical, Hayan Health Networks, Inc., and JVC Investment Partners.
Learn More

May 18, 2020

UChicago Medicine gets $10 Million for Cancer Research

The gift from longtime health care executive David Jonas aims to improve emerging treatments that use the body's own immune system to fight the disease.
Learn More

April 20, 2020

Pi-Cardia Closes a $27 Million Financing led by Sofinnova Partners

Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today it has closed a $27 million round of financing, led by Sofinnova Partners, a leading European life sciences venture capital firm, and joined by Professor Jacques Séguin, Chairman of the company, with further participation from existing investors.
Learn More

October 3, 2019

Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Program

Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Company’s ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in acute myeloid leukemia.
Learn More

July 29, 2019

Magenta Medical Closes Funding Round Led by NEA In Its First-Ever Life Sciences Investment in Israel

Magenta Medical, the developer of heart failure solutions based on proprietary miniaturized blood pump technology, today announced a financing round led by global venture capital firm New Enterprise Associates (NEA), with participation from existing investors, including Pitango Venture Capital, JVC Investment Partners and a group of private investors led by Prof. Jacques Seguin (CoreValve, ReCor).
Learn More

April 13, 2018

Novartis-AveXis Deal Could Be Game-Changer for Chicago

Chicago scored a major win April 9, but it barely registered with most local business leaders. The triumph was Novartis' eye-popping $8.7 billion buyout of a largely unknown startup called AveXis. It was far and away the biggest acquisition yet of a Chicago-area biotech company, more than three times the size of the next largest deal—the 2015 sale of Lake Forest-based PharMEDium to AmerisourceBergen for $2.58 billion.
Learn More

April 5, 2018

Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Chicago scored a major win April 9, but it barely registered with most local business leaders. The triumph was Novartis' eye-popping $8.7 billion buyout of a largely unknown startup called AveXis. It was far and away the biggest acquisition yet of a Chicago-area biotech company, more than three times the size of the next largest deal—the 2015 sale of Lake Forest-based PharMEDium to AmerisourceBergen for $2.58 billion.
Learn More

November 21, 2015

AmerisourceBergen to Buy PharMEDium for $2.58 Billion

David Jonas doesn't like to sit idle. He plays tennis, not golf. He's an early riser, often starting his day with a run of 4 to 5 miles on an empty stomach. When he retired from Baxter International after 25 years, he started a new company. It just sold for $2.58 billion.
Learn More

PharMEDium - LEK Consulting

L.E.K.’s CEO Stuart Jackson, discusses PharMEDium's extraordinary growth trajectory.
Learn More
Image
650 Dundee Road, Suite 380, Northbrook, IL 60062
P: 847.960.3840 | E: info@jvcmanagement.com

Investing our own capital in people with great vision, technologies and promise.

© JVC Investment Partners, All Rights Reserved.